Nicole Allen1, Tessa J Barrett1, Yu Guo2, Michael Nardi1, Bhama Ramkhelawon3, Caron B Rockman3, Judith S Hochman1, Jeffrey S Berger4. 1. Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA. 2. Division of Biostatistics, Department of Population Health, New York University School of Medicine, New York, NY, USA. 3. Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, NY, USA. 4. Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, NY, USA; Division of Hematology, Department of Medicine, New York University School of Medicine, New York, NY, USA. Electronic address: Jeffrey.berger@nyumc.org.
Abstract
BACKGROUND AND AIMS: Platelets are a major culprit in the pathogenesis of cardiovascular disease (CVD). Circulating monocyte-platelet aggregates (MPA) represent the crossroads between atherothrombosis and inflammation. However, there is little understanding of the platelets and monocytes that comprise MPA and the prevalence of MPA in different CVD phenotypes. We aimed to establish (1) the reproducibility of MPA over time in circulating blood samples from healthy controls, (2) the effect of aspirin, (3) the relationship between MPA and platelet activity and monocyte subtype, and (4) the association between MPA and CVD phenotype (coronary artery disease, peripheral artery disease [PAD], abdominal aortic aneurysm, and carotid artery stenosis). METHODS AND RESULTS: MPA were identified by CD14+ monocytes positive for CD61+ platelets in healthy subjects and in patients with CVD. We found that MPA did not significantly differ over time in healthy controls, nor altered by aspirin use. Compared with healthy controls, MPA were significantly higher in CVD (9.4% [8.2, 11.1] vs. 21.8% [11.5, 44.1], p < 0.001) which remained significant after multivariable adjustment (β = 9.1 [SER = 3.9], p = 0.02). We found PAD to be associated with a higher MPA in circulation (β = 19.3 [SER = 6.0], p = 0.001), and among PAD subjects, MPA was higher in subjects with critical limb ischemia (34.9% [21.9, 51.15] vs. 21.6% [15.1, 40.6], p = 0.0015), and significance remained following multivariable adjustment (β = 14.77 (SE = 4.35), p = 0.001). CONCLUSIONS: Circulating MPA are a robust marker of platelet activity and monocyte inflammation, unaffected by low-dose aspirin, and are significantly elevated in subjects with CVD, particularly those with PAD.
BACKGROUND AND AIMS: Platelets are a major culprit in the pathogenesis of cardiovascular disease (CVD). Circulating monocyte-platelet aggregates (MPA) represent the crossroads between atherothrombosis and inflammation. However, there is little understanding of the platelets and monocytes that comprise MPA and the prevalence of MPA in different CVD phenotypes. We aimed to establish (1) the reproducibility of MPA over time in circulating blood samples from healthy controls, (2) the effect of aspirin, (3) the relationship between MPA and platelet activity and monocyte subtype, and (4) the association between MPA and CVD phenotype (coronary artery disease, peripheral artery disease [PAD], abdominal aortic aneurysm, and carotid artery stenosis). METHODS AND RESULTS:MPA were identified by CD14+ monocytes positive for CD61+ platelets in healthy subjects and in patients with CVD. We found that MPA did not significantly differ over time in healthy controls, nor altered by aspirin use. Compared with healthy controls, MPA were significantly higher in CVD (9.4% [8.2, 11.1] vs. 21.8% [11.5, 44.1], p < 0.001) which remained significant after multivariable adjustment (β = 9.1 [SER = 3.9], p = 0.02). We found PAD to be associated with a higher MPA in circulation (β = 19.3 [SER = 6.0], p = 0.001), and among PAD subjects, MPA was higher in subjects with critical limb ischemia (34.9% [21.9, 51.15] vs. 21.6% [15.1, 40.6], p = 0.0015), and significance remained following multivariable adjustment (β = 14.77 (SE = 4.35), p = 0.001). CONCLUSIONS: Circulating MPA are a robust marker of platelet activity and monocyte inflammation, unaffected by low-dose aspirin, and are significantly elevated in subjects with CVD, particularly those with PAD.
Authors: Michael S Garshick; Michael Tawil; Tessa J Barrett; Charissa M Salud-Gnilo; Michael Eppler; Angela Lee; Jose U Scher; Andrea L Neimann; Sanja Jelic; Nehal N Mehta; Edward A Fisher; James G Krueger; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-05 Impact factor: 8.311
Authors: Tessa J Barrett; Martin Schlegel; Felix Zhou; Mike Gorenchtein; Jennifer Bolstorff; Kathryn J Moore; Edward A Fisher; Jeffrey S Berger Journal: Sci Transl Med Date: 2019-11-06 Impact factor: 17.956
Authors: Man K S Lee; Michael J Kraakman; Dragana Dragoljevic; Nordin M J Hanssen; Michelle C Flynn; Annas Al-Sharea; Gopalkrishna Sreejit; Camilla Bertuzzo-Veiga; Olivia D Cooney; Fatima Baig; Elizabeth Morriss; Mark E Cooper; Emma C Josefsson; Benjamin T Kile; Prabhakara R Nagareddy; Andrew J Murphy Journal: Arterioscler Thromb Vasc Biol Date: 2021-01-14 Impact factor: 8.311
Authors: Verena Rolfes; Lucas Secchim Ribeiro; Ibrahim Hawwari; Lisa Böttcher; Nathalia Rosero; Salie Maasewerd; Marina Lima Silva Santos; Tomasz Próchnicki; Camila Meirelles de Souza Silva; Carlos Wagner de Souza Wanderley; Maximilian Rothe; Susanne V Schmidt; H James Stunden; Damien Bertheloot; Magali Noval Rivas; Cor Jesus Fontes; Luzia Helena Carvalho; Fernando Queiroz Cunha; Eicke Latz; Moshe Arditi; Bernardo Simoes Franklin Journal: Cell Rep Date: 2020-05-12 Impact factor: 9.423